#results #STRONGHF #study #show #clear #advantages
- The primary endpoints of the STRONG-HF study demonstrated a significant reduction in death from all causes or readmissions for acute heart failure at Day 180, when the study strategy was implemented
- Rapid, simultaneous uptitration of the therapies and close follow-up led to an improved quality of life for the patients.
- The Roche electrosys® NTperBNP Biomarker is an integral part of the treatment strategy, which requires rapid up-titration and close follow-up after an Admission in acute cardiac insufficiency
Basel, November 9, 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the publication of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure (STRONG-HF) study in patients suffering from acute heart failure were hospitalized. The study, which involves the use of Roche Elecsys’ NT-proBNP biomarker, was terminated early due to superior efficacy in the active arm of the study versus the usual standard of care, as it was considered unethical to continue usual care.
Implementation of the study strategy in clinical routine …
Read on GNW: The results of the STRONG-HF study show clear advantages for
